Summary by Futu AI
Alterity Therapeutics, a biotechnology company, announced the presentation of three posters at the American Academy of Neurology (AAN) 2024 Annual Meeting, which took place from April 13-18 in Denver, Colorado. The presentations focused on the company's research in Parkinson’s disease and Multiple System Atrophy (MSA), including data from the ATH434-201 Phase 2 clinical trial. ATH434, Alterity's lead candidate, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration and has shown promise in preclinical studies. The Phase 2 trial data presented at AAN included baseline fluid biomarkers, neuroimaging, and clinical data from 65 participants with early-stage MSA. The trial aims to demonstrate the efficacy of ATH434 in modifying the disease by targeting labile cellular iron and α-synuclein aggregation. Additionally, the bioMUSE natural...Show More